High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21)

Leukemia Research

Volumn 26, Issue 6, 2002, Pages 539-543

  Palmieri, Salvatore ^a   Sebastio, Lucia ^a   Mele, Giuseppina ^a   Annunziata, Mario ^a   Annunziata, Silvana ^a   Copia, Carolina ^a   Viola, Assunta ^a   De Simone, Mariacarla ^a   Pocali, Barbara ^a   Schiavone, Ettore Mariano ^a   Ferrara, Felicetto ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; High dose cytarabine; t(8; 21)

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; KARYOTYPE; MALE; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 0036243208     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00177-1     Document Type: Article

References (35)

1. Chromosome aberrations in de novo acute myeloid leukemia in adults: Clinical implications
2. Incidence of chromosomal abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia
3. Prognostic significance of karyotype in de novo acute myeloid leukemia
4. Clinical significance of cytogenetics in acute myeloid leukemia
5. On behalf of the medical research council adult and children's leukaemia working parties. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients into the MRC AML 10 trial
6. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
7. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia
8. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications
9. Long-term survival of patients with acute myeloid leukemia
10. Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with "curablity" of experimental leukemia
11. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results
12. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy
13. Double induction strategy for acute myeloid leukemia: The effect of high dose cytarabine with mitoxantrone instead of standard dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
14. A randomised study of high dose cytarabine in induction in acute myeloid leukaemia
15. A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukaemia: A Southwest Oncology Group study
16. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia
17. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
18. Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetis subtype
19. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high dose cytarabine are administered
20. Proposed revised criteria for the classification of acute myeloid leukemia
21. Immunophenotype analysis enables a correct prediction of t(8;21) in acute myeloid leukemia
22. Early blastic transformation of a myeloproliferative disorder with t(8;21) and progressive aberrations of chromosome 8
23. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: Flow cytometry analysis of in vivo and in vitro effects on cell maturation
24. Nonparametric estimation from incomplete observations
25. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
26. Therapy of acute myeloid leukemia: Towards a patient oriented, risk adapted approach
27. Acute myeloid leukemia: Therapeutic indications